Clopidogrel is a thienopyridine that irreversibly inhibits platelet P2Y12 receptors and adenosine diphosphate (ADP) mediated platelet aggregation. It is a prodrug that requires activation in the liver by cytochrome P450 enzymes (CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6) . Dual antiplatelet therapy with clopidogrel and aspirin has become the mainstay of treatment of patients with a...

Synthesis and Antiplatelet Aggregation Activities In Vitro of N,N’di(3-Substitutedphenyl)-4-Methoxyl Benzene-1,3-Disulfonamides Xiu Jie Liu1*, Chao Qing Wang1, Xiao Wang2, Qing Xiang Zhang1, Kai Liu1 1The College of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin 300384, P.R. China 2Department of Applied Chemistry, Harbin Institute of Technology, Harbin, Heilongjia...

Introduction Case Physiology of Hemostasis Vasoconstriction Primary Hemostasis Platelet Adhesion Platelet Granule Release Reaction Platelet Aggregation and Consolidation Secondary Hemostasis: The Coagulation Cascade Regulation of Hemostasis Pathogenesis of Thrombosis Endothelial Injury Abnormal Blood Flow Hypercoagulability Pharmacologic Classes and Agents Antiplatelet Agents Cyclooxygenase Inh...

Recently, cilostazol has been proposed for the treatment of diabetic patients and their complications. Cilostazol is a selective inhibitor of phosphodiesterase type 3 that appears to have both antiplatelet and anti-proliferative effects [4]. Cilostazol inhibits platelet aggregation in response to ADP, epinephrine, collagen and arachidonic acid, and suppresses the production of platelet derived ...

OBJECTIVES This study sought to assess the influence of type 2 diabetes mellitus (T2DM) and the impact of hypoglycemic treatment (insulin vs. noninsulin) on platelet function profiles in patients treated with dual oral antiplatelet therapy. BACKGROUND Insulin inhibits platelet aggregation by suppressing the P2Y12 pathway. However, T2DM patients have a loss of responsiveness to insulin that le...

Use of antiplatelet agents is becoming increasingly common, and their management may require new strategies if neuroaxial techniques are to be employed in patients who will not tolerate discontinuation of antiplatelet therapy. The patient was a 46-year-old man with a past medical history significant for coronary artery disease and who had undergone 14 stents. He developed stent thrombosis (ST) ...

BACKGROUND AND OBJECTIVES The prevalence of arthritis, which is often treated with celecoxib, is high in patients with coronary artery disease. Furthermore, celecoxib has been reported to reduce restenosis after coronary stenting by inhibiting expression of the proto-oncogene Akt. A concern is that celecoxib increases thrombogenicity by inhibiting the synthesis of prostacyclin in endothelial ce...

OBJECTIVE Reduced antiplatelet drug efficacy occurs in conditions of increased platelet turnover, associated with increased proportions of drug-free, that is, uninhibited, platelets. Here, we detail mechanisms by which drug-free platelets promote platelet aggregation in the face of standard antiplatelet therapy. APPROACH AND RESULTS To model standard antiplatelet therapy, platelets were treat...

a series of novel 2-aminopyrimidine and 2-substituted-4,6-diaminopyrimidine derivatives have been synthesized and their anti platelet aggregation activities were assessed against adp and arachidonic acid- induced platelet aggregation in human plasma using light transmission aggregometry. none of the compounds showed satisfactory activity against the aggregation induced by adp. however, satisfac...